| Summary: | In following study we examined whether blood arsenic (As) levels combined with specific polymorphisms in <i>MT1B</i>, <i>GSTP1</i>, <i>ABCB1</i>, <i>NQO1</i>, <i>CRTC3</i>, <i>GPX1</i>, <i>SOD2</i>, <i>CAT</i>, <i>XRCC1</i>, <i>ERCC2</i> can be used as a marker for the detection of colorectal cancer (CRC) among Polish women. A retrospective case-control study of CRC included 83 CRC cases and 78 healthy controls. From each study participant pre-treatment peripheral blood was collected for As level measurement by inductively coupled–plasma mass spectrometry (ICP-MS). We estimated the odds ratio (OR) of the association between blood-As levels and CRC using multivariable unconditional logistic regression models. A low blood-As level (0.27–0.67 µg/L) was associated with an increased frequency of CRC (OR: 3.69; <i>p</i> = 0.005). This correlation was significantly greater when participants carried particular gene variants: <i>CAT</i>, rs1001179-nonCC (OR: 19.4; <i>p</i> = 0.001); <i>ABCB1</i> rs2032582–CC (OR: 14.8; <i>p</i> = 0.024); <i>GPX1</i> rs1050450-CC (OR: 11.6; <i>p</i> = 0.002) and <i>CRTC3</i> rs12915189-nonGG (OR: 10.3; <i>p</i> = 0.003). Our study provides strong evidence that low blood-As levels are significantly associated with increased CRC occurrence and that particular gene variants significantly enhanced this correlation however, due to the novelty of these findings, we suggest further validation before a definitive statement that the combined effect of low blood-As levels with specific gene polymorphisms is a suitable CRC biomarker.
|
|---|